エヌプレート薬剤に関する洞察と市場予測：2032年

エヌプレート（ロミプロスチム）は、コルチコステロイド、免疫グロブリン、脾臓摘出術で十分な効果が得られない成人の慢性ITP患者において、血小板数の減少を治療するために、他の特定の薬剤や脾臓摘出術が十分に奏効しない場合に使用される合成蛋白製剤です。

エヌプレートは、出血のリスクを下げるために血小板数を約50,000/μLに保ちます。エヌプレートは血小板数の正常化には使用されないです。18歳未満の患者におけるエヌプレートの安全性と有効性は不明です。エヌプレートはTPO受容体に結合して活性化することにより血小板産生を増加させるが、その機序は内因性TPOに類似しています。日本では、本剤は重症再生不良性貧血患者の治療薬としても承認されています。

免疫性血小板減少症（ITP）患者には、週1回1mcg/kgを皮下注射します。血小板反応に基づいて投与量を調節します。エヌプレートは、内因性TPOに類似したメカニズムであるTPO受容体に結合し活性化することにより、血小板産生を増加させます。

当レポートでは、主要7ヶ国におけるエヌプレート市場について調査し、市場の概要とともに、2023年～2032年の売上予測データ、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 ITPに対するエヌプレートの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• 規制上のマイルストーン
• その他の開発活動
• 製品概要

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 エヌプレート市場の評価

• ITPに対するエヌプレートの市場展望
• 主要7ヶ国市場分析
  • 主要7ヶ国におけるITPに対するエヌプレートの市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: NPLATE, Clinical Trial Description, 2023
• Table 2: NPLATE, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: NPLATE Market Size in the 7MM, in USD million (2019-2032)
• Table 6: NPLATE Market Size in the US, in USD million (2019-2032)
• Table 7: NPLATE Market Size in Germany, in USD million (2019-2032)
• Table 8: NPLATE Market Size in France, in USD million (2019-2032)
• Table 9: NPLATE Market Size in Italy, in USD million (2019-2032)
• Table 10: NPLATE Market Size in Spain, in USD million (2019-2032)
• Table 11: NPLATE Market Size in the UK, in USD million (2019-2032)
• Table 12: NPLATE Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: NPLATE Market Size in the 7MM, USD million (2019-2032)
• Figure 2: NPLATE Market Size in the United States, USD million (2019-2032)
• Figure 3: NPLATE Market Size in Germany, USD million (2019-2032)
• Figure 4: NPLATE Market Size in France, USD million (2019-2032)
• Figure 5: NPLATE Market Size in Italy, USD million (2019-2032)
• Figure 6: NPLATE Market Size in Spain, USD million (2019-2032)
• Figure 7: NPLATE Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: NPLATE Market Size in Japan, USD million (2019-2032)

“"NPLATE Drug Insight and Market Forecast - 2032" ” report provides comprehensive insights about NPLATE for immune thrombocytopenic purpura (ITP) in the seven major markets. A detailed picture of the NPLATE for ITP in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the NPLATE for ITP. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the NPLATE market forecast analysis for ITP in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in ITP.

Drug Summary:

NPLATE (romiplostim) is a synthetic protein medicine used when certain other medicines, or surgery to remove the spleen, have not worked well enough to treat low blood platelet counts in adults with chronic ITP who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.

NPLATE keeps the platelet count at about 50,000/µL to lower the risk of bleeding. NPLATE is not used to normalize the platelet count. The safety and efficacy of NPLATE are not known in people under the age of 18. NPLATE increases platelet production by binding and activating the TPO receptor, whose mechanism is analogous to endogenous TPO. In Japan, this drug is also approved for the treatment of patients with severe aplastic anemia.

Dosage

For patients with ITP ¬ the recommended initial dose is 1 mcg/kg once weekly as a subcutaneous injection. Adjust dose based on platelet response.

Mechanism of action

NPLATE increases platelet production by binding and activating the TPO receptor, a mechanism analogous to endogenous TPO.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the NPLATE description, mechanism of action, dosage and administration, research and development activities in immune thrombocytopenic purpura (ITP).
• Elaborated details on NPLATE regulatory milestones and other development activities have been provided in this report.
• The report also highlights the NPLATE research and development activities in ITP across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around NPLATE.
• The report contains forecasted sales of NPLATE for ITP till 2032.
• Comprehensive coverage of the late-stage emerging therapies for ITP.
• The report also features the SWOT analysis with analyst views for NPLATE in ITP.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

NPLATE Analytical Perspective by DelveInsight

In-depth NPLATE Market Assessment

This report provides a detailed market assessment of NPLATE for immune thrombocytopenic purpura (ITP) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

NPLATE Clinical Assessment

The report provides the clinical trials information of NPLATE for ITP covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for immune thrombocytopenic purpura (ITP) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence NPLATE dominance.
• Other emerging products for ITP are expected to give tough market competition to NPLATE and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of NPLATE in ITP.
• Our in-depth analysis of the forecasted sales data of NPLATE from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the NPLATE in ITP.

Key Questions:

• What is the product type, route of administration and mechanism of action of NPLATE?
• What is the clinical trial status of the study related to NPLATE in immune thrombocytopenic purpura (ITP) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the NPLATE development?
• What are the key designations that have been granted to NPLATE for ITP?
• What is the forecasted market scenario of NPLATE for ITP?
• What are the forecasted sales of NPLATE in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to NPLATE for ITP?
• Which are the late-stage emerging therapies under development for the treatment of ITP?

Table of Contents

1. Report Introduction

2. NPLATE Overview in ITP

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestone
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. NPLATE Market Assessment

• 5.1. Market Outlook of NPLATE in ITP
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of NPLATE in the 7MM for ITP
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of NPLATE in the United States for ITP
  • 5.3.2. Market Size of NPLATE in Germany for ITP
  • 5.3.3. Market Size of NPLATE in France for ITP
  • 5.3.4. Market Size of NPLATE in Italy for ITP
  • 5.3.5. Market Size of NPLATE in Spain for ITP
  • 5.3.6. Market Size of NPLATE in the United Kingdom for ITP
  • 5.3.7. Market Size of NPLATE in Japan for ITP

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options